Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 03, 2024 2:54pm
151 Views
Post# 35861305

RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

I can & only will post on what I see as published public documents.
The accelerated approval? A wonderful option. 
I believe they could qualify, yet have not indicated they are applying.
Therfore that option is one of many. 
I would be delighted to wake up to a news release hearing about an accelerated approval situation.
likewise a takeover offer from a pharma partner.
or partnership 
Regardless of any of those options Onc MUST provide an update, before the end of Q1.
To remain listed on NAS they need to show 12 momths of cash on hand, on an ongoing basis.
That is why they post in the PDF presentation 12+ months of cash.
So, while you can call me names, misinformed etc etc.
im on the same page you are. I hold a lot if Onc shares, I 100% believe in the science.
and am in this until they get bought out or a successful business deal.
People yamer on & on about dillution.
I offer a question?
They are still around after 20+ years. Now in a very solid position.
Mutiple options of success.
Only failure is if they give up.
They have zero debt, over 12 months of cash flow. Yes they sold shares to do that.
had they not, the company would be closed & the SP would be zero.
it is easy  to criticize. Yet, few have offered any viable alternatives.
Funny, I posted that I agree 100% with Notable , yet he still calls me misinformed etc etc.
Strange bunch in this open form world.
i do stand by my opinion, they need to announce something before end of Q1.
who knows, maybe accelerated approval?
My instinct is still on a complete buyout, with Roche.  

Notable, chill man...I'm on your same team.
The $ 1 billion to $10 billion buyout $$$ available. No denying.
The comparables, ONC is worth many multiples of its existing SP.
They have fast track approval already. Thst was issued by the FDA & based on trial outcomes & potential market opportunities.
There are all very positive indicators.
what we do not know... is the next step.


 

 

 

 

<< Previous
Bullboard Posts
Next >>